Pds biotech announces circulating tumor dna results for versamune® hpv in immunocerv trial published in clinical cancer research

Data confirms versamune ® hpv has potential as a broadly effective treatment of hpv16-associated cancers – initiation of phase 3 trial in hpv16-positive hnscc planned for q1 2025
PDS Ratings Summary
PDS Quant Ranking